Intervention: Nirsevimab

Ezpeleta

Spain
|
2023-2023
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Ocana de Sentuary

France
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Coma

Spain
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Primary care
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Coma 2

Spain
|
2023-2025
  • General population
  • Infants (<1 year)
  • Hospital
  • Primary care
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Costantino

Italy
|
2022-2025
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Perramon-Malavez

Spain
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Maglione

Italy
|
2023-2025
  • General population
  • Infants (<1 year)
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Vera-Punzano

Spain
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Barbas Del Buey

Spain
|
2023-2024
  • General population
  • Infants (<1 year)
  • Community
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

SPIRAV

France
|
2025-2025
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Pregnant women
  • Hospital
  • Outpatient clinic
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Vaccination
  • Nirsevimab
  • Abrysvo

IRIS

Netherlands
|
2025
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Primary care
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

NIRSE-GAL

Spain
|
2023-2026
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Primary care
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab